DYN
Dyne Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$18.16
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$3.0B
Trailing P/E
Forward P/E
-6.09
Rev Growth
Profit Margin
0.0%
ROE
-58.9%
Analyst Target
$39.50
Recommendation
STRONG BUY
About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet0.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: WATCH · Score: 33.5 · Rank: #4863
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$2.3B
Price/Book
3.15
Beta
1.080
Analysts
16
Total Debt
$168.7M
Rec. Mean
1.44
Short Ratio
13.06
Short % Float
0.2%
Employees
263

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 16 analysts at Strong Buy.
Price: $18.16 | Target: $38.25 (+111%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+111%
The Fundamentals
Profit Margin0.0%
ROE-58.9%
Forward P/E-6.1
Market Cap$3.0B
Position Sizing Scenarios
Stop: $15.44 (-15%) | Entry: $18.16
SharesCostProfit to TargetR:R
To Consensus ($38.25, 16 analysts)
10$181.60+$200.90 (111%)7.4R
50$908.00+$1,004.50 (111%)7.4R
100$1,816.00+$2,009.00 (111%)7.4R
Risk Factors
  • Elevated short interest (13.06 days to cover)
The Verdict
Dyne Therapeutics, Inc. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
58.4
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-7.0%
worst expected daily loss, 19 in 20 days
CVaR 95%
-12.9%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
-0.37
above 1.0 is good
Max Drawdown
-85.5%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
80
Liquidity Grade
HIGHLY LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
NEAR_UPPER
Beta
Relative Volume
1.0x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
IDYA0.481
XNCR0.480
HQH0.447
NRIX0.446
CRNX0.446
Inverse Correlated
TickerCorrelation
BAES.L-0.237
MAZAYA.KW-0.193
AGILQ-0.187
STC.KW-0.163
ELWT-0.155
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Friday
Best Month
Aug
Worst Month
Jan
Fri-Mon Effect
-1.2547557774017517
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+2.2%
3M Return
+14.6%
6M Return
-14.3%
12M Return
+58.6%
Momentum Rank
#1637
Momentum Signal
UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access